AICentralResources
AI Tool Comparison

Comparing as AI Medical Research & Clinical Decision Support
Insilico Medicine vs BenevolentAI

Compare features, pricing, pros & cons, and user ratings to decide which AI tool is best for your needs.

VS
Insilico Medicine official logo and brand icon

Insilico Medicine

Enterprise
Visit WebsiteFull Review
BenevolentAI official logo and brand icon

BenevolentAI

Enterprise
Visit WebsiteFull Review

Verdict by Category

AI content generation failed. Refresh the page to try again.
View Insilico Medicine View BenevolentAI
Feature & Spec Matrix

Detailed Comparison26 Criteria

Complete side-by-side breakdown of specifications, capabilities, and feature parity

Swipe horizontally to compare features
Feature / Spec
Insilico Medicine
Insilico Medicine
BenevolentAI
BenevolentAI
Pricing Model
EnterpriseCustom Enterprise Biotech / Pharma Licensing for PandaOmics, Chemistry42, and inClinico — Partnership inquiry
EnterpriseBenevolentAI operates through enterprise pharma collaboration agreements and platform licensing — there is no self-serve access or published pricing. Revenue models include: discovery collaborations with pharma companies (AstraZeneca, Merck) structured as multi-year agreements with upfront fees and milestones; licensing of its knowledge exploration tools as standalone software to pharma R&D organizations; and advancing its own clinical pipeline to inflection points for licensing or co-development. Total funding raised is approximately $1.9B, with the company listed on Euronext Amsterdam (AMS: BAI). Contact BenevolentAI through benevolent.com for partnership and platform licensing inquiries.
Starting Price
Custom / Contact Sales
Custom / Contact Sales
Free Plan & Trial Scope
Difference
No free access — platform licensing and drug discovery collaborations via enterprise agreements
No free access — enterprise pharma partnerships and platform licensing via sales team
User Rating Score
Unrated
Unrated
Ideal Workflow / Use Case
Difference
Pharmaceutical companies and biotechs seeking to accelerate drug discovery from target identification to clinical prediction using generative AI and automated chemistry
Pharmaceutical companies and researchers needing AI-powered knowledge mining for novel drug target identification and disease hypothesis generation in complex diseases
Enterprise & Scalability
Difference
Pharma.AI platform available for licensing and collaboration agreements with major pharma companies; HKEX listed (3696); regulatory filings in multiple jurisdictions; automated robotic lab integration; multi-country R&D centers
Euronext Amsterdam listed (AMS: BAI), $1.9B total raised, in-house wet lab facilities in Cambridge UK, strategic collaborations with AstraZeneca and Merck, HIPAA/GDPR compliant data practices, enterprise licensing for knowledge exploration tools
Core Categories
AI Healthcare ToolsAI Research & Education Tools
AI Healthcare ToolsAI Research & Education Tools
Pharma.AI end-to-end platform: PandaOmics (target ID), Chemistry42 (molecule design), InClinico (clinical prediction)
Difference
Insilico Medicine Advantage
Not listed
Rentosertib (ISM001-055) — world's most advanced fully AI-discovered drug in Phase 3 for IPF
Difference
Insilico Medicine Advantage
Not listed
31+ drug programs across 29 targets in cancer, fibrosis, CNS, immunity, and aging
Difference
Insilico Medicine Advantage
Not listed
Generative AI for de novo molecule design against novel and known drug targets
Difference
Insilico Medicine Advantage
Not listed
Automated robotic laboratory in Suzhou connected directly to the AI platform
Difference
Insilico Medicine Advantage
Not listed
300+ patents filed, 200+ peer-reviewed publications in top scientific journals
Difference
Insilico Medicine Advantage
Not listed
Multi-billion dollar licensing partnerships with Sanofi, Fosun Pharma, and Exelixis
Difference
Insilico Medicine Advantage
Not listed
Chemistry42 generative AI designs novel molecules not found in existing chemical libraries
Difference
Insilico Medicine Advantage
Not listed
PandaOmics AI for target identification using multi-omics, literature, and clinical data
Supported
Supported
Listed on Hong Kong Stock Exchange (HKEX: 3696) — founded 2014 at Johns Hopkins University
Difference
Insilico Medicine Advantage
Not listed
Target identification and disease hypothesis generation from multimodal biomedical data
Difference
Not listed
BenevolentAI Advantage
In-house wet lab facilities in Cambridge UK for AI hypothesis validation
Difference
Not listed
BenevolentAI Advantage
Clinical pipeline: BEN-8744 (Phase 1, ulcerative colitis), BEN-28010 (preclinical, glioblastoma), BEN-34712 (preclinical, ALS)
Difference
Not listed
BenevolentAI Advantage
Strategic collaborations with AstraZeneca and Merck for AI-powered drug target discovery
Difference
Not listed
BenevolentAI Advantage
Knowledge exploration tools for pharma partners — licensed separately from drug pipeline
Difference
Not listed
BenevolentAI Advantage
Integrated AI + wet lab model: AI generates hypotheses, scientists validate in physical experiments
Difference
Not listed
BenevolentAI Advantage
Multi-disease focus: oncology, rare disease, fibrosis, CNS, immunology, and cardiovascular
Difference
Not listed
BenevolentAI Advantage
Listed on Euronext Amsterdam (AMS: BAI) — $1.9B total raised since founding in 2013
Difference
Not listed
BenevolentAI Advantage
Offices in London HQ, Cambridge wet labs, and New York
Difference
Not listed
BenevolentAI Advantage
Insilico Medicine icon

Insilico Medicine Pros & Cons

Pros

  • World's most advanced fully AI-designed drug — rentosertib in Phase 3 for IPF (2026)
  • End-to-end Pharma.AI platform covers target ID through clinical prediction in one system
  • 300+ patents and 200+ peer-reviewed papers — strongest scientific publication record in AI drug discovery
  • Revenue grew from $4.5M to $85M in 3 years — commercially proven licensing model
  • Automated robotic lab in Suzhou closing the loop between AI design and physical testing
  • Global presence: US, China, Canada, Middle East — with partnerships across big pharma
  • Listed on Hong Kong Stock Exchange (HKEX: 3696) — public company with institutional backing

Cons

  • Pipeline still in early-to-mid clinical stages — commercial drugs not yet approved
  • Business model complexity — revenue from licensing deals is lumpy and milestone-dependent
  • Dual-track model (platform + internal pipeline) adds operational complexity
  • Regulatory timelines in pharma are long — AI acceleration doesn't remove all delays
  • Listed on HKEX (Hong Kong) — less accessible to US institutional investors
BenevolentAI icon

BenevolentAI Pros & Cons

Pros

  • Fully integrated AI + wet lab model — unique among AI drug discovery platforms
  • AstraZeneca and Merck partnerships validate the platform's target identification quality
  • In-house wet labs in Cambridge close the loop between AI prediction and biology
  • Euronext Amsterdam listed (AMS: BAI) — $1.9B raised, publicly accountable
  • Phase 1 clinical data for BEN-8744 (ulcerative colitis) represents real clinical progress
  • Multiple disease areas covered: oncology, rare disease, CNS, fibrosis, and immunology
  • Knowledge exploration tools can be licensed separately from drug pipeline

Cons

  • Listed on Euronext Amsterdam (AMS: BAI) — less accessible to US retail investors
  • Clinical pipeline still in early stages — no approved drugs yet
  • Smaller than competitors like Recursion in terms of funding and team size
  • Revenue dependent on collaboration milestones — lumpy and uncertain
  • Wet-lab operations add cost complexity vs. pure software drug discovery peers
Head-to-Head Battle Cards

Popular Comparisons

Direct feature matrices, pricing breakdowns, and real-world benchmark duels

All AI Healthcare Tools comparisons
Recursion Pharmaceuticals vs Insilico Medicine Comparison Battle Card - Features, Pricing & Review in AI Healthcare Tools
Direct head-to-head AI tool comparison between Recursion Pharmaceuticals and Insilico Medicine in AI Healthcare Tools featuring side-by-side feature matrix, pricing tiers, and benchmark verdict.
AI Healthcare ToolsCompare
Tempus AI vs Insilico Medicine Comparison Battle Card - Features, Pricing & Review in AI Healthcare Tools
Direct head-to-head AI tool comparison between Tempus AI and Insilico Medicine in AI Healthcare Tools featuring side-by-side feature matrix, pricing tiers, and benchmark verdict.
AI Healthcare ToolsCompare
Insilico Medicine vs DAX Copilot Comparison Battle Card - Features, Pricing & Review in AI Healthcare Tools
Direct head-to-head AI tool comparison between Insilico Medicine and DAX Copilot in AI Healthcare Tools featuring side-by-side feature matrix, pricing tiers, and benchmark verdict.
AI Healthcare ToolsCompare
BenevolentAI vs Freed AI Comparison Battle Card - Features, Pricing & Review in AI Healthcare Tools
Direct head-to-head AI tool comparison between BenevolentAI and Freed AI in AI Healthcare Tools featuring side-by-side feature matrix, pricing tiers, and benchmark verdict.
AI Healthcare ToolsCompare